Literature DB >> 16203447

Risk factors and medical follow-up of drug users tested for hepatitis C--can the risk of transmission be reduced?

M A Serfaty1, A Lawrie, B Smith, A M Brind, J P Watson, E Gilvarry, M F Bassendine.   

Abstract

Of 1728 patients attending a regional drug and alcohol clinic, 202 were considered at risk of hepatitis C virus (HCV). Forty-nine per cent (99/202) agreed to testing-67% (67) were HCV antibody positive. Age and a history of needle sharing was the significant factor associated with positive HCV status. Patients on methadone maintenance medication were more-likely to have been HCV positive, but significantly (p = 0.005) less likely to have shared needles in the previous year. Seventy-three per cent (49/67) attended for follow-up at a "liver clinic". Fifty per cent were infected with genotype 1a. Eighteen patients were biopsied and all were abnormal, ranging from mild hepatitis to severe fibrotic hepatitis. Attendance for medical follow-up was poor, which emphasizes the importance of preventative measures such as methadone maintenance programmes for reducing the spread of HCV.

Entities:  

Year:  1997        PMID: 16203447     DOI: 10.1080/09595239700186721

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  9 in total

1.  Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment.

Authors:  D Best; A Noble; E Finch; M Gossop; C Sidwell; J Strang
Journal:  BMJ       Date:  1999-07-31

2.  Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working?

Authors:  V D Hope; A Judd; M Hickman; T Lamagni; G Hunter; G V Stimson; S Jones; L Donovan; J V Parry; O N Gill
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

3.  Hepatitis C virus: laboratory surveillance in England and Wales, 1992-2004.

Authors:  U Gungabissoon; M A Balogun; M E Ramsay
Journal:  Epidemiol Infect       Date:  2006-09-06       Impact factor: 2.451

4.  Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.

Authors:  Benedikt Fischer; Emma Haydon; Jürgen Rehm; Mel Krajden; Jens Reimer
Journal:  J Urban Health       Date:  2004-09       Impact factor: 3.671

5.  Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy.

Authors:  T Asselah; D Vidaud; A Doloy; N Boyer; M Martinot; M Vidaud; D Valla; P Marcellin
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

Review 6.  Controversies in and challenges to our understanding of hepatitis C.

Authors:  Robert G Batey
Journal:  World J Gastroenterol       Date:  2007-08-21       Impact factor: 5.742

7.  Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.

Authors:  Bruce R Schackman; Jared A Leff; Devra M Barter; Madeline A DiLorenzo; Daniel J Feaster; Lisa R Metsch; Kenneth A Freedberg; Benjamin P Linas
Journal:  Addiction       Date:  2015-01       Impact factor: 7.256

8.  The hepatitis C cascade of care: identifying priorities to improve clinical outcomes.

Authors:  Benjamin P Linas; Devra M Barter; Jared A Leff; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Arthur Y Kim; Bruce R Schackman
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.752

9.  Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings.

Authors:  Sabrina A Assoumou; Abriana Tasillo; Jared A Leff; Bruce R Schackman; Mari-Lynn Drainoni; C Robert Horsburgh; M Anita Barry; Craig Regis; Arthur Y Kim; Alison Marshall; Sheel Saxena; Peter C Smith; Benjamin P Linas
Journal:  Clin Infect Dis       Date:  2018-01-18       Impact factor: 20.999

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.